| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 3, 2025 |
| Accession Number: | 0001013762-25-004209 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 3, 2025 |
| Accession Number: | 0001013762-25-004209 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (NASDAQ:HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University. The n
*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease NEW YORK, June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) and Silo Pharma, Inc. (NASDAQ:SILO) today announced the formation of a strategic joint venture to develop and commercialize a first-in-class treatment for obesity and metabolic disease based on technology exclusively licensed from the U.S. Department of Veterans Affairs (VA).
SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. Patent Application No. 17/954,858 (titled "Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders") that Silo licenses from Columbia University. The to-be-issued patent will further strengthen Silo's IP protection for its lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent is expected
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
8-K - Silo Pharma, Inc. (0001514183) (Filer)
8-K - Silo Pharma, Inc. (0001514183) (Filer)
424B4 - Silo Pharma, Inc. (0001514183) (Filer)
SC 13G - Silo Pharma, Inc. (0001514183) (Subject)
SC 13G - Silo Pharma, Inc. (0001514183) (Subject)
SC 13G/A - Silo Pharma, Inc. (0001514183) (Subject)